High dose cytarabine and mitoxantrone: An effective induction regimen for high-risk Acute Myeloid Leukemia (AML)

Leukemia and Lymphoma

Volumn 53, Issue 3, 2012, Pages 445-450

  Larson, Sarah M ^a   Campbell, Nicholas P ^a   Huo, Dezheng ^a   Artz, Andrew ^a   Zhang, Yanming ^a   Gajria, Devika ^a   Green, Margaret ^a   Weiner, Howie ^a   Daugherty, Christopher ^a   Odenike, Olatoyosi ^a   Godley, Lucy A ^a   Hyjek, Elizabeth ^a   Gurbuxani, Sandeep ^a   Thirman, Michael ^a   Sipkins, Dorothy ^a   Van Besien, Koen ^a   Larson, Richard A ^a   Stock, Wendy ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Chemotherapeutic approaches; Cytogenetics; Myeloid leukemias and dysplasias

Indexed keywords

CYTARABINE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BACTEREMIA; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONGESTIVE HEART FAILURE; CYTOGENETICS; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; EMPYEMA; EPIDURAL HEMORRHAGE; FEBRILE NEUTROPENIA; FEMALE; HEART ATRIUM ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCOSAL TOXICITY; OUTCOME ASSESSMENT; PERICARDIAL EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SEPSIS; SINUSITIS; SURVIVAL RATE; TREATMENT RESPONSE;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOME ABERRATIONS; COMBINED MODALITY THERAPY; CYTARABINE; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FMS-LIKE TYROSINE KINASE 3; HEMATOLOGIC DISEASES; HUMANS; INFECTION; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASM PROTEINS; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84863137986     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.621562     Document Type: Article

References (41)

1. zbowska A, Robak T, Pluta A.et al. Cladribine [1] ibine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly eff ective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: A fi nal report of the Polish Adult Leukemia Group. Eur. J. Haematol. 2008;80: 115-126.
2. v an der Holt B, Lowenberg B, Burnett AK.et al. Th e value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 2005;106:2646-2654. (Pubitemid 41510736)
3. R owe JM, Neuberg D, Friedenberg W.et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: A trial by the Eastern Cooperative Oncology Group. Blood 2004;103:479-485. (Pubitemid 38140076)
4. P reisler HD, Venugopal P, Gregory SA.et al. Poor prognosis acute myelogenous leukemia: 1 - response to treatment with high dose cytarabine/mitoxantrone/ethyolAmifostine). Leuk Res 2000;24: 671-680. (Pubitemid 30495501)
5. L owenberg B, Suciu S, Archimbaud E.et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy-the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: Fi nal report. European rganization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J. Clin. Oncol. 1998;16:872-881. (Pubitemid 28115455)
6. G oldstone AH, Burnett AK, Wheatley K.et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: The results of the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1302-1311.
7. F aderl S, Ravandi F, Huang X.et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and highrisk myelodysplastic syndrome. Blood 2008;112:1638-1645.
8. Estey EH, Th all PF, Giles FJ.et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: Comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood 2002;99:4343-4349. (Pubitemid 34627199)
9. B uchner T, Hiddemann W, Wormann B.et al. Double induction strategy for acute myeloid leukemia: The eff ect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: A randomized trial by the German AML Cooperative Group. Blood 1999;93:4116-4124. (Pubitemid 29279253)
10. A rlin Z, Case DC, Jr., Moore J.et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. Leukemia 1990;4:177-183. (Pubitemid 20099889)
11. A nderson JE, Kopecky KJ, Willman CL.et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: A Southwest Oncology Group study. Blood 2002;100:3869-3876. (Pubitemid 35396851)
12. D aenen S, Lowenberg B, Sonneveld P.et al. Effi cacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON). Leukemia 1994;8:6-10. (Pubitemid 24032811)
13. H o AD, Lipp T, Ehninger G.et al. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia-an active and well-tolerated regimen. J. Clin. Oncol. 1988;6:213-217. (Pubitemid 18065924)
14. K antarjian HM, Estey EH, Keating MJ. Treatment of therapyrelated leukemia and myelodysplastic syndrome. Hematol Oncol Clin North Am 1993;7:81-107. (Pubitemid 23052975)
15. T akeyama K, Seto M, Uike N.et al. Th erapy-related leukemia and myelodysplastic syndrome: A large-scale Japanese study of clinical and cytogenetic features as well as prognostic factors. Int J Hematol 2000; 71:144-152.
16. W alter RB, Kantarjian HM, Huang X.et al. Eff ect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: A combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. J. Clin. Oncol. 2010;28:1766-1771.
17. R aza A, Preisler HD, Day R.et al. Direct relationship between remission duration in acute myeloid leukemia and cell cycle kinetics: A leukemia intergroup study. Blood 1990;76:2191-2197.
18. Quinones VW. Recruitment of acute myeloid leukemia cells into cell cycle using timed sequential high dose cytarabine and mitoxantrone at fi rst relapse. Blood 1996: 3147a.
19. Preisler HD, Venugopal P, Gregory SA.et al. High remission rate in acute myeloblastic leukemia with only two days of chemotherapy. Leuk Lymphoma 2001;41:333-336. (Pubitemid 32499415)
20. G rimwade D, Walker H, Oliver F.et al. Th e importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. Th e Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92:2322-2333. (Pubitemid 28452973)
21. Slovak ML, Kopecky KJ, Cassileth PA.et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075-4083.
22. Extermann M. Measuring comorbidity in older cancer patients. Eur. J. Cancer 2000;36:453-471. (Pubitemid 30136223)
23. S mith TJ, Khatcheressian J, Lyman GH.et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J. Clin. Oncol. 2006;24: 3187-3205. (Pubitemid 46638957)
24. Cheson BD, Bennett JM, Kopecky KJ.et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Th erapeutic Trials in Acute Myeloid Leukemia. J. Clin. Oncol. 2003;21:4642-4649. (Pubitemid 46594039)
25. Baer MR, George SL, Dodge RK.et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002;100:1224-1232. (Pubitemid 34864276)
26. Greenberg PL, Lee SJ, Advani R.et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995). J. Clin. Oncol. 2004;22: 1078-1086. (Pubitemid 41095041)
27. K olitz JE, George SL, Marcucci G.et al. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood 2010;116:1413-1421.
28. Koreth J, Schlenk R, Kopecky KJ.et al. Allogeneic stem cell transplantation for acute myeloid leukemia in fi rst complete remission: Systematic review and meta-analysis of prospective clinical trials. JAMA 2009;301:2349-2361.
29. Yanada M, Matsuo K, Emi N.et al. Effi cacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in fi rst disease remission: A metaanalysis. Cancer 2005;103:1652-1658. (Pubitemid 40490026)
30. S ierra J, Storer B, Hansen JA.et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: The eff ect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood 1997;89:4226-4235. (Pubitemid 27220974)
31. W ong R, Shahjahan M, Wang X.et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 2005;1:108-114. (Pubitemid 40186207)
32. Duval M, Klein JP, He W.et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J. Clin. Oncol. 2010;28:3730-3738.
33. C ashen AF, Schiller GJ, O'Donnell MR.et al. Multicenter, phase II study of decitabine for the fi rst-line treatment of older patients with acute myeloid leukemia. J. Clin. Oncol. 2010;28:556-561.
34. Blum W, Garzon R, Klisovic RB.et al. Clinical response and miR- 29b predictive signifi cance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A 2010;107:7473-7478.
35. K antarjian HM, Erba HP, Claxton D.et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J. Clin. Oncol. 2010;28:549-555.
36. Kayser S, Dohner K, Krauter J.et al. Th e impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011;117:2137-2145.
37. Godley LA, Njiaju UO, Green M.et al. Treatment of therapyrelated myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leuk Lymphoma 2010;51:995-1006.
38. B rown RA, Herzig RH, Wolff SN.et al. High-dose etoposide and cyclophosphamide without bone marrow transplantation for resistant hematologic malignancy. Blood 1990;76:473-479. (Pubitemid 20251812)
39. C ortes J, Estey E, O'Brien S.et al. High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. Cancer 2001;92: 7-14. (Pubitemid 32623034)
40. Liu Yin JA, Wheatley K, Rees JK.et al. Comparison of ' sequential ' versus ' standard ' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): Results of the UK Medical Research Council AML-R trial. Br. J. Haematol. 2001;113:713-726. (Pubitemid 32524396)
41. Stone RM, Moser B, Sanford B.et al. High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. Leuk Res 2011;35(3):329-333.